key: cord-0754372-wkqn15li
authors: Pourrajab, Fatemeh
title: Targeting the glycans: A paradigm for host‐targeted and COVID‐19 drug design
date: 2021-05-24
journal: J Cell Mol Med
DOI: 10.1111/jcmm.16585
sha: d7fc7f116556341753b07df979f6aa0a13020e87
doc_id: 754372
cord_uid: wkqn15li

There is always a need for new approaches for the control of virus burdens caused by seasonal outbreaks, the emergence of novel viruses with pandemic potential and the development of resistance to current antiviral drugs. The outbreak of the 2019 novel coronavirus‐disease COVID‐19 represented a pandemic threat and declared a public health emergency of international concern. Herein, the role of glycans for the development of new drugs or vaccines, as a host‐targeted approach, is discussed where may provide a front‐line prophylactic or threats to protect against the current and any future respiratory‐infecting virus and possibly against other respiratory pathogens. As a prototype, the role of glycans in the coronavirus infection, as well as, galectins (Gal) as the glycan‐recognition agents (GRAs) in drug design are here summarized. Galectins, in particular, Gal‐1 and Gal‐3 are ubiquitous and important to biological systems, whose interactions with viral glycans modulate host immunity and homeostatic balance.

of the SGP S has been identified which was found fully conserved among clinical isolates of SARS-Cov-2 worldwide. 1, 3, 5, 6 Out of a dozen or more potential drugs to treat infection are already in clinical trials. One of them is the wellknown antimalarial drug, chloroquine (CLQ), and its alternative hydroxychloroquine (CLQ-OH), which have attained notifications in clinics. In vitro and infected patients, both compounds displayed that can efficiently inhibit severe acute respiratory system Cov-2 (SARS-Cov-2) infection. The mechanism that has been revealed until now is through increasing the low pH of intracellular endosomes (required for virus fusion), interfering with the host glycosylation process, as well as, masking sialoglycans at the cellular surface where blocking virus-host receptor interaction and viral entry (needed for subsequent viral replication and syncytial formation). [7] [8] [9] Identification of this new mechanism of action of CLQ and CLQ-OH (interfering with the host glycosylation and masking sialoglycans) provides supports for the use of these repositioned drugs to cure patients infected with SARS-Cov-2. 3, 5 There are reports for the prevention of influenza by intranasal targeting of host receptors using engineered proteins masking the cell surface glycans. Studies have designed multivalent biologics, engineered carbohydrate-binding agents (CBAs) specific for sialic acid that use sialic acid as a receptor and mask the cell surface receptors. The biologics mask the cell surface receptors recognized by the influenza virus (IV) and could protect mice from a challenge with a lethal dose of 2009 pandemic H1N1 IV. However, there was sufficient virus replication to establish an immune response, potentially protecting the animal from future exposure to the virus. [10] [11] [12] Additionally, there are reports for antiviral activity of iminosugars (eg in the case of HIV-1), whose mechanism of action is through inhibiting ER glucosidases and glycosylation process of cell surface receptors. The ER-glucosidase activity is required for glycosylation of cellular and viral receptors. The iminosugars potently inhibit the release of infectious virion particles and the number of infected cells, however, a barrier to their clinical application, is that they show off-target effects whereby impeding host gut glucosidases leading to diarrhoea and abdominal pains. Additionally, viral spike glycoproteins (SGPs) are glycosylated by the host cell as able to hijack cellular glycosylation. 6, 13 It is, therefore, possible that by the inhibition of the host cell glycosylation process or interfering with glycan interactions at the cellular surface, the SGPs are no longer able to bind to the host glycans. 3, 5 Some mechanisms and features show the important role of glycans in viral infection, as well as, in the development of prophylactics and treatments especially for the development of new vaccines. 6, 12, 13 Furthermore, the host-targeted approach could provide a frontline prophylactic that has the potential to protect against any current and future respiratory-infecting virus and possibly against other respiratory pathogens.

The large spike (S) glycoprotein (GPS) (~200-kDa) on the envelope of CoV virions binds to host-specific receptors whereby mediate virus entry, tissue tropism, and host range; and can affect virus virulence.

CoV GPS is class I viral fusion protein, like IV hemagglutinin (HA), human immunodeficiency virus-1 (HIV-1) envelope GP (Env), Ebola virus GP and paramyxovirus F GPs. 14, 15 There are structural similarities between GPS of SARS-CoV-2, SARS-CoV and MERS-CoV that suggest the possibility for them to share receptors. In SARS-CoV and SARS-CoV-2, the GPS exhibits similarity in structure and sequence of the RBD and the identity in residues critical for ACE2 binding, the majority of which are either highly conserved or shared similar side chain properties. SARS-CoV and SARS-CoV-2 GPS exhibit an overall sequence identity of about 76%, with only 51% identity in NTD, 64% in RBD and 90% in the S2 fusion domain. [16] [17] [18] In comparison, SARS-CoV-2 and MERS-CoV share lower sequence identity in their spikes (~35%), RBDs, or RBM, and yet they recognize the same receptor dipeptidyl peptidase-4 (DPP4). The GPS of the SARS-CoV-2 gene is longer than SARS-CoVs and there are three short insertions in the N-terminal domain, which may confer a sialic acid-binding activity like as MERS-CoV GPS. 1, [16] [17] [18] CoV GPS is separated into two subunits, called S1 and S2, by cellular proteases (host or producing-cell). It first binds to a receptor on the host cell surface through its S1 subunit and then fuses viral and host membranes through its S2 subunit. 14, 15 The S1 subunit of GPS contains two distinctive domains, the N-terminal domain (S1-NTD) and the C-terminal domain (S1-CTD), both of which can function as receptor-binding domains (RBDs). S1-NTD is a carbohydrate-binding domain, (CBD) responsible for recognizing and binding to sugars, while S1-CTD binds protein receptors such as dipeptidyl peptidase-4 (DPP4), angiotensin-converting enzyme 2 (ACE2) and APN, and function as the functional-binding domain (FBD). [1] [2] [3] 19, 20 In the case of the SARS-CoV-2 and MERS-CoV receptor, the human GP CD26 or DPP4 is a key immune-regulatory factor for hijacking and virulence and is widely expressed on epithelial cells in the kidney, alveoli, small intestine, liver, and prostate, and activated leucocytes. These viruses might deregulate antiviral T cell responses due to the stimulation of T cell apoptosis. 1, 21 In the case of the SARS-CoV receptor, the membrane-associated aminopeptidase ACE2 is highly expressed in the lung, vascular endothelia, renal and cardiovascular tissue, and epithelia of the small intestine and testes. 22 ACE2 plays a crucial role in elderly people by regulating the RAS via opposing the actions of Ang II because it has a beneficial role in many diseases such as hypertension, diabetes and cardiovascular disease. 11 Through S1-CTD, SARS and MERS-CoVs bind to ACE2 and DPP4, respectively, while the novel SARS-CoV-2 S1-CTD seems able to utilize both receptors to infect host cells. 1, 2, 20, 23 The S1 subunit is further divided into four β-rich subdomains, designated as A, B, C and D, with subdomains A and B acting as RBDs in different coronaviruses. 17, 24 In SARS-CoV-2 and MERS-CoV, the S1B subdomain recognizes the host receptors ACE2 and DPP4, respectively, while viral initial binding and primary attachment is through the interaction between the S1A subdomain and host α2,3/6-linked Sia.

Herein, the S1B subdomain has a major influence on the virus-host range and tissue tropism, and its receptor tissue localization varies between species. 1, 2, 5, 25 Whereas, the S1A subdomain which participating in the early phase of viral attachment and infection shares conserved structural folds and sugar-binding sites in different viral lectins. 4, 5, 24, 25 Studies reveal that the S1-NTD resembles the structural folds and sugar-binding sites of human galectin-3 (Gal-3), 1, 20, 24 whereas the S1-CTD is aggressively evolving and exploits novel protein receptors to determine the viral specificity of receptor binding and host tropism. 14, 15, 26 It appears to be a successful strategy for viruses to share a lectin structure as a sugar receptor and acquire RBDs with novel specificity or altered specificity for a protein receptor. 14, 16, 25, 27 

Several articles have focused on glycosylation patterns that oc- Additionally, alteration of N-linked glycans on the surface of host cells impairs their ability to support the transduction of an infectious virus such as CoVs and IV. 6, 7, 29 In the case of virus infectivity, the glycosylation pattern can be compositionally different across different species and individuals, an important feature of viral interspecies/ inter-individual transmission potential where influences viral tropism. 6, 13 Additionally, differential organization of viral glycosylation across viral GPs influences not only individual glycan compositions but also the immunological pressure across the viral protein surface that put them principal targets of the neutralizing humoral immune response. 17, 23 In SARS-CoV-2, SARS and MERS-CoV, the overall structure of GPS can resemble each other, but the density and compositions of glycan shielding are markedly different (Figure 1 ). Marked differences exist between the residues 40-318 located at the subdomain S1A in S1-NTD. Moreover, densely glycosylated spike proteins be- The SGP S structure can be divided into the S1 and S2 domains, and the structural domains in the spike protein are located in the order (from C to the N terminus) as: transmembrane (TM), heptad repeats (HRs) in the S2 domain, C-terminal domain (CTD), and N-terminal domain (NTD) in the S1 domain as well as the signal peptide (SP). The S1-CTD is divided into three subdomains SD-SB, while S1-NTD contains subdomain SA. SD-SA is accounted as receptor-binding domain (RBD). (B-D) Glycosylation sites for oligomannose, hybrid and complex-type N-glycans are coloured in green, blue and red, respectively. Unique glycosylation sites for SARS-CoV-2 are dashed in violet, green and blue, the dual recognition of gangliosides and angiotensin-converting enzyme-2 (ACE-2) by SARS-CoV-2 spike (S) protein. The viral protein displays two distinct domains, the tips of which are available for distinct types of interactions (S1-NTD). The receptor-binding domain (S1-CTD) binds to the ACE-2 receptor, and the N-terminal domain (NTD) binds to the ganglioside/sialoglycan-rich domain of the plasma membrane. Lipid rafts, which are membrane domains enriched in gangliosides and cholesterol, provide a perfect attractive interface for adequately positioning the viral S protein at the first step of the infection process sulphates provides a measurable effect on virus adhesion and is required for viral attachment. [33] [34] [35] [36] Tissue-specific glycosylation is a key determinant of interspecies viral transmission potential and can lead to the targeting of vulnerable tissues within a host. For example, the capacity of the avian influenza virus (AIV) HA to interact with both α2,3-and α2,6-linked Sia has been shown to facilitate cross-species barrier of the virus from birds to humans. Besides, the differential expression of these Sia structures between the upper and lower respiratory tracts in humans can shape the distribution of influenza infection within an individual. 6, 13, 28 Sialic acid-widespread distribution of the human respiratory tract predisposes as a potential receptor and binding site for human and zoonotic viruses, as well as, their transmission. 37 There is enough evidence that shows sialoglycans play a critical role in human zoonotic virus biology, and broaden the therapeutic options to block the replication of viruses attacking the respiratory system such as pandemic COVID-19 and AIV epidemics. 1, 7, 10, 13 Remarkably, shifting in the host of swine IVs during their adaptation is mediated by shifts in the HA Sia-binding affinity, just as an early adaptation step of avian H9N2 strains. Only two mutations in the H9N2 AIV HA (at positions A190V and T212I), led to its adaptation to the respiratory epithelium of pigs and enhances Sia-binding activity and virulence. 29, 38 Or, a single point mutation in the highly patho- Among the enveloped viruses that recognize Sia-containing receptors are members of the families Coronaviridae, Paramyxoviridae and Orthomyxoviridae. 4 CoV GPSs share structural features in their sugar-binding sites (S1-NTD) resembling the galectin-3 folding structure in humans. 24 The key saccharide-binding residues are located in the S1-NTD subdomain A which determines the host tropism and viral attachment at the early phase of viral infection. 2, 3, 24 These residues should be strictly conserved in the Gal3-like fold of domain A (eg Tyr162, Glu182, Trp184 and His185 in BCoV) that involved in interacting with sialoglycans in a similar way. 26 The sialyl-lactose binding domain of the COVID-19 agent is identified at residues 111-158, which is fully conserved among clinical isolates worldwide, and shows attachment to membrane lipid rafts, and facilitates contact with the ACE-2 receptor ( Figure 2 ). 3, 41 The increased transmissibility of the COVID-19 agent in comparison with MERS and SARS-CoV is addressed to its engagements with sialoglycans in lipid rafts; glycoproteins and gangliosides. 3, 8 Human

The N-glycome of the human lung contains extremely large complex-type N-glycans with linear poly-N-acetyllactosamine (PL) n extensions, which are predominantly terminated in α2,3-linked

Sia. There are smaller N-glycans lack PL while are enriched in α2,6linked Sia. There are also large glycosphingolipid-glycans, which also consist of linear PL, terminating in mainly α2,3-linked Sia. 42 The Increased expression of Siglecs in human alveolar monocytes is accompanied by an enhanced intracellular level of IL-1β and IL-10.

Siglec-1 interacts specifically with sialylated viral envelope proteins and gangliosides, but not with host membrane gangliosides. This mechanism likely leads to an increased viral capture and thus prolonged exposure to the cell surface receptors CD4 and CCR5 on the macrophage surface ( Figure 3) . 28, 31, 32 Erythrocyte membranes are constituted with lipids, some of which are also known to promote viral fusion in T cells and virus enrichment. These lipids include sphingolipids and their glycosylated derivatives that form part of the blood group milieu of the red blood cell. In reports, lipid rafts comprising of glycosphingolipids and cholesterol were considered to be sufficient for viral fusion without the need for co-receptors. A Sia-binding virus that manages to make its way into the bloodstream would immediately encounter this extensive cell surface and can bind to RBCs wherein getting appropriate mechanisms to allow latter invasion and replication. 47, 48 Erythrocytes are enriched in α2,6/3-Sia residues whereby can be Importantly, the ganglioside-binding domain in SARS-CoV-2 S1-NTD could selectively interact with the lipid rafts of human erythrocytes and enrich infectious CoV virions in the body. The tip of S1-NTD contains ~290 amino acids, particularly targets gangliosiderich microdomains in cell membranes, such as lipid rafts in RBCs.

There is an over-representation of aromatic and basic residues in the 100-175 region of S1-NTD including segment; 129-K VCE F Q F CNDP F LGV YY H K NN K S W MESE FR -158, which also contains Gly, Pro, and/or Ser residues. CLQ and CLQ-OH drugs by binding to ganglioside-binding motifs can efficiently prevent viral S1-NTD interaction with lipid rafts of the host cell ( Figure 4) . 3, 32 Virus binding to erythrocytes leads to erythrophagocytosis (via asialyllactose-binding receptors or DC-SIGN or L-SIGN) ( Figure 3 ).

and haemoglobin in the blood, while leads to increased plasma concentration of free iron and hyperferritinemia. 9 

Accordingly, the glycom of the viral envelope and the host cellular surface has a crucial role in enabling efficient transmission of the pathogen and/or entry into its susceptible target cells. 6, 28 Antiviral agents that interact with the surface glycans may, therefore, compromise the efficient entry of the virus into its sus- Collectively, data indicate that Gal-1 preferentially has anti-IV activity by binding to viral HA and inhibiting its infectivity. Thus, Gal-1 may be further explored as a novel therapeutic agent for influenza. 12 virus to the body is inhibited. In masking the Sialo-galacto-glycans, the spike GPs cannot bind the host receptors that could block virus attachment and human respiratory epithelium infection. 15, 24, 40, 58 From the literature, it is interpreted that intranasal administration of Gal-3 before or during the early phase of virus infection would reduce viral load, accompanying inflammation, tissue damage and mortality in the susceptible host. 11, 12, 59 In a mouse model for IAV infection, Gal-3 was discharged on the airway epithelia and caused the release of pro-inflammatory mediators that induce the expression of antiviral genes, including IFNs (β & γ), to inhibit IAV replication. 11 As intranasal administration of recombinant Gal-1 in infected mice led to reducing viral load, accompanying inflammation, tissue damage and mortality in the murine model infected with influenza virus. 15, 58 The protective effect of Gal-3 at the airway epithelia against roles that they play in the innate immune system. The diverse, at times, paradoxical roles that they may play in the innate immune system are related to their different interactions at the molecular level which is dependent on their structure-activity relationship and needs to be dissected. 5, 6, 11, 21 Thereby, surface glycans as an important class of microbial signature that is recognized by a variety of host cell lectins can function as both recognition and effectors against viral and bacterial infection. In therapeutic design, surface glycans can 'subvert' viral adhesion to or cause to gain entry into the host cells. Herein, host-intranasal administration of a galectin, before or during the early phase of virus infection, is proposed that recognize specific glycan ligands and subverting viral adhesion and promoting host immune response. Data suggest that galectins (here in Gal-1 and -3) can potentially be used as viral therapeutic targets or antagonists.

There is no conflict of interest to be declared. 

https://orcid.org/0000-0002-1724-5392

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors

Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection

The symmetry of viral sialic acid binding sites-implications for antiviral strategies

Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and humancoronavirusNL63spikeprotein-mediatedentry by altering the glycan processing of angiotensinI-convertingenzyme2

Exploitation of glycosylation in enveloped virus pathobiology

Hydroxychloroquine, a lesstoxicderivative of chloroquine, is effective in inhibitingSARS-CoV-2infection in vitro

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Prevention of influenza by targeting host receptors using engineered proteins

The role of galectins in virus infection -a systemic literature review

Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

Structure, function, and evolution of coronavirus spike proteins

Identification of the receptor-binding domain of the spike glycoprotein of human betacoronavirus HKU1

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

The structural biology of galectin-ligand recognition: current advances in modeling tools, protein engineering, and inhibitor design

COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Structural basis for human coronavirus attachment to sialic acid receptors

Species-specific colocalization of Middle East respiratory syndrome coronavirus attachment and entry receptors

Glycan shield and fusion activation of a deltacoronavirus spike glycoprotein fine-tuned for enteric infections

Crystal structure of bovine coronavirus spike protein lectin domain

HIV-1 capture and transmission by dendritic cells: the role of viral glycolipids and the cellular receptor siglec-1

Mutations during the adaptation of H9N2A vian influenza virus to the respiratory epithelium of pigs enhance sialic acid binding activity and virulence in mice

A small molecule inhibits virion attachment to heparan sulfate-or sialic acid-containing glycans

Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes

Red blood cells: chasing interactions

Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells

Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans

Host determinants of MERS-CoV transmission and pathogenesis

Distinct roles for sialoside and protein receptors in coronavirus infection

Sialic acid receptor detection in the human respiratory tract: evidence for widespread distribution of potential binding sites for human and avian influenza viruses

Overview of current therapeutics and novel candidates against influenza, respiratory syncytial virus, and middle east respiratory syndrome coronavirus infections

The spike protein of SARS-CoV -a target for vaccine and therapeutic development

Receptor recognition mechanisms of coronaviruses: a decade of structural studies

COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression

The human lung glycome reveals novel glycan ligands for influenza A virus

Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein

Humanspecific regulation of alpha 2-6-linked sialic acids

Sialylation and muscle performance: sialic acid is a marker of muscle ageing

Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smokeinduced pathology in vitro

Multifarious roles of sialic acids in immunity

Erythrocyte Lysate from HIV-1-infected individuals contains HIV-1 RNA

H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome

Hemophagocytic syndrome: pitfalls in its diagnosis

DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

Structural characterization of N-linked glycans in the receptor binding domain of the SARS-CoV-2 spike protein and their interactions with human lectins

Galectins as pattern recognition receptors: structure, function, and evolution

Roles of galectins in infection

Structural analysis of the evolutionary origins of influenza virus hemagglutinin and other viral lectins

Molecular basis for pathogenicity of human coronaviruses

Functions of galectins as 'self/non-self'-recognition and effector factors

Microbe-host interactions are positively and negatively regulated by galectin-glycan interactions

Galectin-3 inhibition by a small-molecule inhibitor reduces both pathological corneal neovascularization and fibrosis

Galectin-3 enhances avian H5N1 influenza A virus-induced pulmonary inflammation by promoting NLRP3 inflammasome activation

How to cite this article: Pourrajab F. Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design